China All Vaccine revenue is nearly 2374.63 M USD In 2016
Wednesday, 07 Nov, 2018
In the last several years, the market of China All Vaccine changed greatly, with an average growth rate of -6.47%. In 2016, revenue of China All Vaccine is nearly 2374.63 M USD; the actual sale is about 555.85 M Dose.
The average price of China All Vaccine is in the increasing trend, from 2.93 USD/Dose in 2012 to 4.27 USD/Dose in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of China All Vaccine includes Polio, Pertussis, Diphtheria, Tetanus, BCG, Rabies, Hepatitis B, Pneumococcal, Hepatitis A, Varicella, Influenza and others and the proportion of Pertussis, Diphtheria and Tetanus in 2016 is about 20.15%, and the proportion is in fluctuation trend from 2012 to 2016.
China All Vaccine is widely used by adults and children. The most proportion of China All Vaccine is children, and the sales market share in 2016 is 65.71%. The children proportion are decreasing.
Market competition is not intense. CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH, NuoCheng Bio, Hualan Bio, Kangtai, SANOFI PASTEUR S.A., Novartis, GSK, etc. are the leaders of the industry in China, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.